Residency · Residency · Child Adolescent Psychiatry

ADHD Medication Diversion and Misuse in Adolescents

Overview

Stimulant diversion — the transfer of prescribed medication to non-prescribed individuals for non-medical use — is a common and growing concern in adolescent ADHD management. Prevalence of stimulant misuse among college students ranges from 5-35% depending on the population studied, and among adolescents with ADHD prescriptions, 15-25% report being asked to give, sell, or trade their medication. The prescriber bears clinical and ethical responsibility for balancing access to effective ADHD treatment against the real risks of diversion, particularly in the context of increasing ADHD diagnosis rates and periodic stimulant shortages.

Epidemiology of Stimulant Diversion

Prevalence Data

The National Survey on Drug Use and Health estimates that approximately 5 million Americans aged 12 and older report non-medical stimulant use annually, with the highest rates in the 18-25 year age group, particularly among college students. Among high school students, 5-10% report non-medical stimulant use. Diversion is more common in schools with higher socioeconomic status, and the vast majority of diverted stimulants come from peers with prescriptions rather than from online sources or drug dealers.

Motivations for Misuse

The most common motivation for non-medical stimulant use is academic performance enhancement, cited by 60-70% of those who misuse these medications, which is why stimulants have acquired the label "study drugs" on college campuses. Recreational use for euphoria or socializing accounts for 10-20%, weight loss for 5-15%, and curiosity or peer pressure for the remainder. A meaningful subset of non-prescribed users may actually be self-medicating for undiagnosed ADHD, a possibility that should prompt clinical rather than punitive evaluation when identified.

Routes of Diversion

Giving medication away is the most common route, often motivated by a genuine desire to help friends who are struggling academically. Selling medication — with stimulant pills fetching $5-20 each on college campuses — may be financially motivated. Trading medication for other substances, homework, or favors also occurs. Theft from family members' prescriptions is another route.

Risk Factors for Diversion

Patient-Related Factors

Risk is highest among older adolescents and young adults (college age represents the peak risk period). Comorbid substance use disorder or conduct disorder increases risk, as does social pressure from peers requesting medication. The perception that stimulants are "safe" or "just like coffee" lowers perceived barriers to sharing. Patients taking immediate-release formulations — which are easier to share, crush, or snort — face higher diversion risk, as do those who feel the medication is unnecessary or was prescribed against their wishes.

Prescription-Related Factors

Immediate-release formulations carry higher abuse potential and are easier to divert. Excess supply, which may accumulate during drug holidays or dosing changes, creates opportunity. Lack of monitoring or accountability and multiple prescribers unknowingly providing concurrent prescriptions also contribute.

Environmental Factors

Competitive academic environments, fraternity and sorority culture, normalization of stimulant misuse in peer groups, and easy access to stimulant-sharing social networks all elevate diversion risk.

Health Risks of Stimulant Misuse

Acute Risks

Cardiovascular risks include tachycardia, hypertension, arrhythmias, and, rarely, sudden cardiac death — particularly with intranasal or intravenous use, or in individuals with undiagnosed cardiac conditions. Psychiatric risks include anxiety, panic attacks, paranoia, and psychosis, especially at high doses. Insomnia and appetite loss are common. Seizures can occur at high doses. Risk is significantly elevated when stimulants are combined with alcohol (which masks sedation, leading to dangerous intoxication) or with other stimulants such as caffeine or cocaine.

Chronic Risks

Chronic non-medical use can lead to tolerance, escalating doses, and stimulant use disorder as defined by the DSM-5. Chronic insomnia, weight loss, and malnutrition may result from sustained use. Cardiovascular complications accumulate with prolonged exposure. Chronic anxiety and depression may follow stimulant withdrawal.

Routes of Administration Increasing Risk

Intranasal use (crushing and snorting tablets) produces faster onset and higher peak levels than oral administration. Intravenous injection is rare in adolescents but carries the highest risk. Using doses higher than prescribed or combining stimulants with alcohol, cannabis, or other substances all significantly increase the risk of adverse outcomes.

Prescriber Responsibilities and Risk Mitigation

Assessment Strategies

Before prescribing stimulants, clinicians should screen for substance use history using validated tools such as the CRAFFT for adolescents. Assessment for conduct disorder, antisocial traits, and peer influences is important. Direct inquiry about diversion — "Has anyone ever asked you for your medication?" — should be routine. The patient's own attitude toward medication should be assessed, as ambivalence increases diversion risk. Comorbid conditions that may predispose to misuse should also be identified.

Prescription-Level Interventions

Several prescription-level strategies can reduce diversion risk. Extended-release and prodrug formulations should be favored — lisdexamfetamine (Vyvanse) has lower abuse potential because it requires enzymatic cleavage, and extended-release formulations have slower onset, reducing the euphoric effect. Excessive supply should be avoided by prescribing only the amount needed and limiting 90-day supplies for high-risk patients. Prescription drug monitoring programs (PDMPs) should be checked for concurrent prescriptions and patterns of early refills. For patients at high diversion risk, non-stimulant alternatives (atomoxetine, guanfacine ER, clonidine ER, or viloxazine ER) eliminate abuse potential entirely. Immediate-release formulations should be limited to situations where extended-release options are not feasible or affordable.

Monitoring Strategies

Regular follow-up visits every 1-3 months maintain clinical contact and accountability. Pill counts, where patients bring their medication bottles to appointments, can detect discrepancies. Urine drug screening can verify that the patient is actually taking their prescribed medication rather than diverting it. Refill patterns should be tracked, with early refill requests warranting investigation. School communication, obtained with appropriate consent, can verify that medication effects are consistent with reported use. Behavioral contracts — written agreements about medication use, storage, and consequences — formalize expectations.

Education and Counseling

Patients and families should understand the legal consequences of diversion: stimulants are Schedule II controlled substances, and distributing them is a felony. Safe medication storage in a locked cabinet under parental control is a practical intervention. For younger adolescents, parents should manage medication directly rather than allowing self-administration. Patients should be helped to develop responses for peer requests — phrases like "My doctor counts my pills" or "My parents monitor my medication" provide a face-saving way to decline. Normalizing the conversation — "Many teens with ADHD meds get asked to share. How do you handle that?" — reduces stigma and encourages honest discussion.

Ethical Considerations

Balancing Access vs. Abuse Potential

There is an inherent tension between under-treating ADHD (which itself increases risk for substance use, academic failure, and psychosocial impairment) and over-prescribing stimulants (which contributes to diversion). Refusing to prescribe stimulants to all adolescents because of diversion risk would deny effective treatment to the large majority who use their medication appropriately. Risk mitigation strategies allow most patients to receive stimulants safely while identifying and managing the subset at higher diversion risk.

The "Enhancement" Debate

The use of stimulants by healthy individuals for cognitive enhancement raises ethical questions distinct from ADHD treatment. Importantly, the evidence that stimulants provide significant cognitive enhancement in non-ADHD individuals is actually quite limited — the perceived benefit often exceeds the actual benefit. Prescribers should ensure they are treating genuine ADHD through thorough diagnostic assessment rather than providing performance enhancement.

Stigma and Criminalization

Adolescents caught diverting stimulants may face criminal charges, school expulsion, and long-term legal consequences. The prescriber's role is clinical, not that of law enforcement, but addressing diversion within the treatment relationship is essential. It is equally important to avoid stigmatizing patients with ADHD by conflating their legitimate treatment with drug misuse — ADHD is a real disorder that deserves real treatment.

<image>An infographic showing the pathways of stimulant diversion from prescription to misuse. Start with a prescribed patient, then show branches: giving to peers (most common), selling, trading, and theft. For each pathway, show the motivations (academic enhancement, recreational use, weight loss, self-medication). Include statistics on prevalence at each step and the demographic most associated with each pathway. Use a flow diagram format.</image>

<image>A risk mitigation strategy pyramid for stimulant prescribers treating adolescents with ADHD. At the base: universal precautions (thorough assessment, PDMP check, family education, safe storage). Middle tier: moderate-risk strategies (extended-release/prodrug formulations, regular follow-up, behavioral contracts). Top tier: high-risk interventions (urine drug screening, pill counts, non-stimulant alternatives, frequent visits). Label each tier with the corresponding risk level of the patient population.</image>

Clinical Pearls

Stimulant diversion is common and should be proactively addressed with every adolescent prescribed stimulants — it should never be ignored or assumed absent. Extended-release formulations and prodrugs (particularly lisdexamfetamine) reduce but do not eliminate diversion and abuse potential. The most common motivation for stimulant misuse among adolescents is academic performance enhancement, not recreational drug use. Prescription drug monitoring programs should be checked before every stimulant prescription to detect multi-provider prescribing. Direct, non-judgmental inquiry about diversion — "Has anyone asked you for your medication?" — should be a routine part of every follow-up visit. Untreated ADHD is itself a risk factor for substance use disorders, and withholding stimulants from appropriate patients does not reduce overall substance use risk. Parental medication management, rather than adolescent self-administration, is a simple and effective risk reduction strategy for younger teens. Non-stimulant medications are a valuable alternative when diversion risk is high, though their lower efficacy for core ADHD symptoms should be weighed in the decision.

References

• Wilens, T.E. et al. (2008). Misuse and diversion of stimulants prescribed for ADHD. JAACAP, 47(1), 21-31.
• McCabe, S.E. et al. (2016). Medical and nonmedical use of prescription stimulants. JAACAP, 55(8), 701-708.
• Faraone, S.V. et al. (2020). The pharmacology of amphetamine and methylphenidate: relevance to the neurobiology of ADHD. Neuroscience & Biobehavioral Reviews, 113, 569-584.
• Clemow, D.B. & Walker, D.J. (2014). The potential for misuse and abuse of medications in ADHD. Postgraduate Medicine, 126(5), 64-81.
• Benson, K. et al. (2015). Misuse of stimulant medication among college students. Pharmacotherapy, 35(2), 96-112.
• Volkow, N.D. & Swanson, J.M. (2003). Variables that affect the clinical use and abuse of methylphenidate. American Journal of Psychiatry, 160(11), 1909-1918.

Read this lecture as Markdown